Ibogaine

Clinical contraindication: Absolute; The clinical literature treats the combination as contraindicated.
Best available evidence: Case reports
Half-life: Not recorded

Named in state rules?

CONot named

ORNot named

NMPending

Cite asPsilodex: ibogaine · v2026.10.02

Clinical data and state rules are separate facts. Both are shown; neither is a decision.

01 Interaction with psilocybin

QT prolongation; fatal cardiac arrhythmias have been reported. Noribogaine persists for days. No data on combination with psilocybin.

Human data with psilocybin: Case reports or surveys only

Evidence types on this record

CRCase reports or online surveys

02 Pharmacology relevant to psilocybin

1 listed · counted on reports

QT-prolonging: Lengthens the QT interval on an ECG, a measure of the heart’s electrical recovery between beats. A long QT raises the risk of a dangerous heart rhythm, more so with other QT-prolonging drugs or low potassium or magnesium. Sources [1][2]

03 State rules

Official text governs

CO4 CCR 755-1

Not named

Not currently a regulated natural medicine in Colorado. The statute allows it to be added; the advisory board recommended it in September 2025 and a research pilot (HB 26-1325) is under way. No provision addresses combining it with psilocybin.

Colorado · checked 2026-09-30

OROAR 333-333

Not named

No provision names this medication or its class.

Oregon · checked 2026-09-30

NM7.35.3 NMAC (proposed)

Pending

New Mexico's clinical rules (proposed 7.35.3 NMAC) are not final. No provision naming this medication has been found.

New Mexico · checked 2026-09-30

04 Conditions to ask about

None linked

No condition named in state rules is linked to this medication.

05 Sources

Knuijver T, Schellekens A, Belgers M, et al. Safety of ibogaine administration in detoxification of opioid-dependent individuals: a descriptive open-label observational study. Addiction 2022;117(1):118–128. — mean max QTc prolongation 95 ms; 50% exceeded 500 ms; prolongation beyond 24 h in 6/14
Koenig X, Hilber K. The anti-addiction drug ibogaine and the heart: a delicate relation. Molecules 2015;20(2):2208–2228. — review of sudden deaths and arrhythmia

Report an error in this record →